Previous investigations on CD38 expression in CTCL have been limited and somewhat inconsistent, particularly in Sézary Syndrome (SS) cells, which exhibited intermediate CD38 staining in treatment-resistant, aggressive CTCL subtypes [15, 18]. This evidence concerns the gene CD38 and synovial sarcoma.